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62 Original ResearchBACKGROUND: Respiratory virus infections are commonly associated with COPD exacerba-
tions, but little is known about the mechanisms linking virus infection to exacerbations.
Pathogenic mechanisms in stable COPD include oxidative and nitrosative stress and reduced
activity of histone deacetylase-2 (HDAC2), but their roles in COPD exacerbations is un-
known. We investigated oxidative and nitrosative stress (O&NS) and HDAC2 in COPD
exacerbations using experimental rhinovirus infection.
METHODS: Nine subjects with COPD (Global Initiative for Chronic Obstructive Lung Disease
stage II), 10 smokers, and 11 nonsmokers were successfully infected with rhinovirus. Markers
of O&NS-associated cellular damage, and inﬂammatory mediators and proteases were
measured in sputum, and HDAC2 activity was measured in sputum and bronchoalveolar
macrophages. In an in vitro model, monocyte-derived THP-1 cells were infected with
rhinovirus and nitrosylation and activity of HDAC2 was measured.
RESULTS: Rhinovirus infection induced signiﬁcant increases in airways inﬂammation and
markers of O&NS in subjects with COPD. O&NS markers correlated with virus load and
inﬂammatory markers. Macrophage HDAC2 activity was reduced during exacerbation and
correlated inversely with virus load, inﬂammatory markers, and nitrosative stress. Sputum
macrophage HDAC2 activity pre-infection was inversely associated with sputum virus load
and inﬂammatory markers during exacerbation. Rhinovirus infection of monocytes induced
nitrosylation of HDAC2 and reduced HDAC2 activity; inhibition of O&NS inhibited
rhinovirus-induced inﬂammatory cytokines.
CONCLUSIONS: O&NS, airways inﬂammation, and impaired HDAC2 may be important
mechanisms of virus-induced COPD exacerbations. Therapies targeting these mechanisms
offer potential new treatments for COPD exacerbations. CHEST 2016; 149(1):62-73KEY WORDS: COPD; host defense; infection; viral disease-nitrotyrosine; 8-OHdG = 8-hydroxy-
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COPD is a rapidly growing global epidemic.1 COPD
exacerbations cause impaired quality of life, accelerated
loss of lung function, and enormous healthcare costs.2
Most exacerbations are a consequence of viral and/or
bacterial infections; the most common viruses identiﬁed
are rhinoviruses.3 The mechanisms of virus-induced
exacerbations remain unclear, however.4 Current
therapies for exacerbations consist of corticosteroids and
antibiotics, but these are not very effective, have frequent
adverse effects, and are focused on bacterial
exacerbations.5,6 New treatments are urgently needed
and developing these requires a better understanding of
the mechanisms of COPD exacerbations.
Pathogenic mechanisms in stable COPD include
oxidative and nitrosative stress (O&NS) and reduced
expression of the antiinﬂammatory enzyme histone
deacetylase-2 (HDAC2).7-9 High levels of reactive
oxygen species and reactive nitrogen species are
generated in COPD, resulting in induction of
proinﬂammatory cytokines and chemokines, mucous
hypersecretion, activation of proteases, and damage toDrs Footitt, Mallia, and Durham contributed equally to this article.
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journal.publications.chestnet.orgcellular components.10 Histone deacetylases remove
acetyl groups on histones and inﬂuence gene
expression. HDAC2 suppresses inﬂammatory gene
expression and is reduced in alveolar macrophages and
lung tissue in COPD, and this is believed to be a key
mechanism of corticosteroid resistance in COPD.8,11
Nitrosylation of tyrosine residues on HDAC2 by
peroxynitrite results in its inactivation12 and reactive
oxygen species activate phosphoinositide 3-kinase,
leading to phosphorylation and inactivation of
HDAC2.13 Therefore, O&NS exerts proinﬂammatory
effects both through direct induction of inﬂammatory
mediators and reduction of the antiinﬂammatory
action of HDAC2.
The roles of O&NS and HDAC2 in COPD exacerbations
are unclear. We have previously demonstrated that
experimental rhinovirus infection induces symptoms,
airﬂow obstruction, and airways inﬂammation in
subjects with COPD.14-16 We hypothesized that
O&NS is increased and HDAC2 activity reduced in
virus-induced COPD exacerbations.Methods
Study Design
Ethical approval for the study was obtained from StMary’s local research
ethics committee (study no. 07/H0712/138) and informed consent
obtained from all subjects. Subjects with COPD (Global Initiative for
Obstructive Lung Disease [GOLD] stage II) and smokers with normal
lung function were recruited according the criteria established in ourprevious study (e-Table 1),15 together with nonsmokers with normal
lung function. The patients with COPD were receiving no inhaled
corticosteroids, long-acting regular bronchodilators, or oral
corticosteroids. Baseline samples of induced sputum and BAL were
obtained approximately 14 days prior to infection and subjects were
inoculated with 10 50% tissue culture infective doses of rhinovirus 16
on day 0, as described previously.15 Sputum sampling was repeated on
subsequent visits on days 3, 5, 9, 12, 15, 21, and 42 postinfection and
bronchoscopy on day 7. Respiratory symptoms were recorded daily
using diary cards, per our previous studies (e-Table 2). A COPD
exacerbation was deﬁned as an increase in the total lower respiratory
score of at least 2 points over baseline for at least 2 consecutive days.
Sputum Assessments
A marker of hydroxyl radical damage to DNA, 8-hydroxy-
2’-deoxyguanosine (8-OHdG); 8-isoprostane, a marker of lipid
peroxidation; and 3-nitrotyrosine (3-NT), a product of tyrosine
nitration mediated by peroxynitrite, were measured in sputum
supernatants using commercially available enzyme immunoassays
(Cayman Chemical Co) according to the manufacturer’s instructions.
Sputum nitrite levels were measured using the Griess assay. The Meso
Scale Discovery platform (Meso Scale Discovery LLC) was used to
measure inﬂammatory mediators in sputum and BAL supernatants.
The mediators measured were the proinﬂammatory cytokines IL-1b,
tumor necrosis factor (TNF)-a, and granulocyte-macrophage colony-
stimulating factor (GM-CSF); the neutrophil chemokine CXCL8/IL-8;
and the protease matrix metalloprotease-9 (MMP-9). Neutrophil
elastase was measured using an enzyme-linked immunosorbent assay
according to the manufacturers’ instructions (Immunodiagnostik AG).
Further details are provided in the e-Appendix.
HDAC2 Immunoprecipitation and Activity
The HDAC2 isoenzyme was isolated from macrophage pellets obtained
from sputum and BAL samples. Immunoprecipitation using a HDAC2
antibody (Insight Biotechnology Ltd) and PureProteome Protein A63
magnetic beads (EMD Millipore) was performed. HDAC activity was
measured using an HDAC activity assay (Cayman Chemicals Co),
the details of which are provided in the e-Appendix. Details of the
experimental protocols of the in vitro infection of THP-1 cells
(a human monocyte cell line) to further investigate the effects of
rhinovirus infection on HDAC2 also are provided in the e-Appendix.
Statistical Analysis
Data are presented as either means or median. Changes from baseline
were analyzed using repeated measures analysis of variance or the
Friedman test, and differences between groups were analyzed usingTABLE 1 ] Baseline Clinical Characteristics of Study Subjec
Characteristic Nonsmokers (n ¼ 11) Smokers (n ¼ 1
Age, y 62.18  1.62 52.50  2.23
Sex, male:female 4:7 4:6
Current smokers 0 10/10
Smoking history,
pack-years
0 32.1  3.02
FEV1, L 3.17  0.17 3.24  0.21
FEV1 % predicted 102.2  3.34 96.60  3.28
FEV1/FVC 77.62  1.09 78.04  2.18
Data given as mean  SEM. NS ¼ nonsmoker; SMK ¼ smoker.
64 Original Researchthe Holm-Sidak multiple comparisons test or the Kruskal-Wallace
test. Correlations between data sets were examined using the
Spearman rank correlation coefﬁcient. Correlations were examined
using peak postinoculation values as in a dynamic and evolving
clinical event, such as a respiratory infection. The temporal
relationships between the induction of the different markers was
variable between individual subjects, and using set days may miss
relationships where timing of events varied. Differences were
considered signiﬁcant for all statistical tests at P values < .05. All
reported P values are two-sided. Analysis was performed using
GraphPad Prism version 6.00 for Windows (GraphPad Software Inc).Results
Study Subjects
The clinical characteristics of the subjects successfully
infected with rhinovirus 16 are shown in Table 1.
Subjects were age and sex matched between the subjects
with COPD and both control groups, but the
nonsmokers were older than the control subjects who
smoked. Cigarette smoke exposure between control
subjects who smoked and subjects with COPD was
matched for pack-year history.
Clinical and Inﬂammatory Responses
Symptoms and Lung Function: All subjects with COPD
experienced an exacerbation following rhinovirus
infection (e-Fig 1).15 All exacerbations were level 1,
according to the American Thoracic Society (ATS)/
European Respiratory Society severity classiﬁcation.17
FEV1 fell signiﬁcantly from baseline in the subjects with
COPD on days 3, 5 (P < .05), 9 (P < .01), 12 (P < .05),
and 15 (P < .01), with a maximum fall of 250 mL
(12.92%) on day 15. There were no signiﬁcant falls from
baseline in FEV1 in the control groups (e-Fig 2).
Sputum Inﬂammatory Cells, Neutrophil Elastase, and
Virus Load: In the subjects with COPD, sputum
inﬂammatory cells were signiﬁcantly increased over
baseline on day 9, and were signiﬁcantly highercompared with the nonsmokers on days 9 and 15
(Fig 1A and e-Table 3). There was no signiﬁcant change
from baseline in the smokers and the nonsmokers.
Sputum neutrophils increased signiﬁcantly from
baseline in the subjects with COPD on day 9 and were
signiﬁcantly higher compared with the smokers on day
12 (Fig 1B). There were no signiﬁcant changes in
numbers of neutrophils in either control group, nor in
numbers of macrophages, lymphocytes, or eosinophils
in any group. Levels of neutrophil elastase in sputum
increased from baseline on days 9 and 15 in the subjects
with COPD and were signiﬁcantly higher in the COPD
group compared with control subjects on day 5 (Fig 1C).
Sputum virus load was increased from baseline on
days 3-15 in the subjects with COPD, on days 5 and 9
in the smokers, and on days 3 and 9 in nonsmokers
(Fig 1D). Sputum virus load was signiﬁcantly higher in
the COPD group compared with both control groups on
day 12 and compared with the nonsmokers on day 15.
Sputum Inﬂammatory Mediators: In the study subjects
with COPD, there were signiﬁcant increases from
baseline in IL-1b, GM-CSF, CXCL8/IL-8, TNF-a, and
MMP-9 in sputum (Fig 2). There was no signiﬁcant
induction of inﬂammatory mediators in the subjects
without COPD apart from IL-1b on day 9 and GM-CSF
on day 21 in the smokers. Sputum mediator levels werets
0) COPD (n ¼ 9) P Values
60.44  3.17 < .05 SMK vs NS
6:3 NS
8/9 .
39.44  3.25 NS
2.31  0.13 < .05 COPD vs NS < .01
COPD vs SMK
68.11  1.58 < .0001 COPD vs SMK and NS
61.58  1.80 < .0001 COPD vs SMK and NS
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Figure 1 – Time course of inﬂammatory cells, neutrophil elastase, and virus load in sputum during experimental rhinovirus infection. A, Total sputum
inﬂammatory cells (neutrophils, macrophages/monocytes, lymphocytes, eosinophils). B, Sputum neutrophils. C, Sputum neutrophil elastase. D, Sputum
virus load. All data are given as mean  SEM. *P < .05; **P < .01; ***P < .001 vs baseline. †P < .05; ††P < .01 COPD vs nonsmokers. #P < .01;
##P < .01 COPD vs smokers.signiﬁcantly higher in the subjects with COPD
compared with the nonsmokers on days 9 and 15 and
for some mediators on days 5, 12, and 21. Levels of
inﬂammatory mediators in BAL both at baseline and
postinoculation were generally lower than in sputum
and are shown in e-Figure 3 and e-Table 4. Correlations
between sputum inﬂammatory mediators, inﬂammatory
cells, and virus load in the subjects with COPD are
shown in Table 2.
O&NS: Prior to infection, sputum 8-OHdG levels were
higher in the COPD group compared with the smokers
(P < .05) and 3-NT levels were higher in the COPD
group compared with nonsmokers (P < .05) and
smokers (P < .001), with no differences between the
groups in baseline levels of nitrite or 8-isoprostane
(Fig 3). Markers of O&NS were all signiﬁcantly induced
following rhinovirus infection in subjects with COPD,
with much smaller induction seen in the smokers, andjournal.publications.chestnet.orgwere signiﬁcantly higher in the subjects with COPD
compared with the subjects without COPD (Figs 3A-D).
Macrophage HDAC2 Activity
At baseline, there were no signiﬁcant differences
between the groups in HDAC2 activity in sputum (data
not shown) or BAL macrophages (Fig 3F). Following
infection, HDAC2 activity in the smoking control
subjects and nonsmoking control subjects did not
change signiﬁcantly from baseline, but tended to
increase (Figs 3E, 3F). In the subjects with COPD, there
was a trend toward reduced HDAC2 activity in both
sputum (P ¼ .064) and BAL macrophages (P ¼ .098)
(Figs 3E, 3F). Sputum HDAC2 activity was signiﬁcantly
lower in the subjects with COPD compared with
nonsmokers on days 5 and 21 (P < .05), and there was a
trend toward lower levels of BAL HDAC2 activity
during exacerbation compared with the nonsmokers
(P ¼ .095) and smokers (P ¼ .059).65
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Figure 2 – Time course of inﬂammatory mediators in sputum during experimental rhinovirus infection in COPD. A, Sputum IL-1b. B, Sputum TNF-a.
C, Sputum GM-CSF. D, Sputum CXCL8/IL-8. E, Sputum MMP-9. All data are given as median  IQR. *P < .05; **P < .01; ***P < .001 vs baseline.
†P < .05; ††P < .01 COPD vs nonsmokers. GM-CSF ¼ granulocyte-macrophage colony-stimulating factor; IQR ¼ interquartile range;
MMP-9 ¼ matrix metalloprotease-9; TNF-a ¼ tumor necrosis factor-a.Correlations
Baseline HDAC2: Sputum macrophage HDAC2 activity
at baseline correlated inversely with peak
postinoculation sputum virus load (P ¼ .022,66 Original Researchr ¼ 0.82), sputum neutrophil elastase (P ¼ .022,
r ¼ 0.81), CXCL8/IL-8 (P ¼ .047, r ¼ 0.71), and
TNF-a (P ¼ .028, r ¼ 0.79) (Table 2). There were no
relationships between baseline HDAC2 activity and[ 1 4 9 # 1 CHES T J A N U A R Y 2 0 1 6 ]
TABLE 2 ] Correlations Between Baseline Sputum HDAC2 Levels and Postinoculation BAL Macrophages HDAC2
Levels and Peak Levels of Sputum Inﬂammatory Mediators and Virus Load
Sputum Inﬂammatory Mediators
Baseline Sputum HDAC2,
P Value (r Value)
Postinoculation BAL Macrophages
HDAC2 P Value (r Value)
Peak sputum virus load .022 (0.82) .
Peak sputum neutrophil elastase .022 (0.81) .0499 (0.67)
Peak sputum CXCL8/IL-8 .047 (0.71) .
Peak sputum TNF-a .028 (0.79) .03 (0.72)
Peak nasal lavage virus load . .0096 (0.8)
Peak sputum GM-CSF . .0499 (0.67)
Peak sputum nitrite . .0125 (0.78)
GM-CSF ¼ granulocyte-macrophage colony-stimulating factor; HDAC2 ¼ histone deacetylase-2; TNF-a ¼ tumor necrosis factor-a.outcomes following infection in the subjects who did not
have COPD.
Oxidative Stress: In the subjects with COPD, peak
sputum 8-isoprostane levels and 8-OHdG levels during
exacerbations correlated with each other (P ¼ .0068,
r ¼ 0.82). 8-OHdG correlated with peak sputum
neutrophil elastase (P ¼ .0125, r ¼ 0.78) and sputum
3-NT levels (P ¼ .0016, r ¼ 0.83).
Nitrosative Stress: Peak sputum 3-NT and sputum
nitrite levels during exacerbation correlated with each
other (P ¼ .0037, r ¼ 0.85). Peak sputum 3-NT level
correlated with peak neutrophil elastase level (P ¼ .0009,
r ¼ 0.9) and peak sputum nitrite level correlated with
peak sputum inﬂammatory cell numbers (P ¼ .0125,
r ¼ 0.778), neutrophil elastase (P ¼ .042, r ¼ 0.68), and
neutrophil numbers (P ¼ .0096, r ¼ 0.8) (Table 3).
HDAC2 Activity: HDAC2 activity in BAL macrophages
in subjects with COPD during exacerbations correlated
inversely with peak nasal-lavage virus load (P ¼ .0096,
r ¼ 0.8), peak sputum GM-CSF (P ¼ .0499,
r ¼ 0.67), TNF-a (P ¼ .03, r ¼ 0.72), neutrophil
elastase (P ¼ .0499, r ¼ 0.67), and sputum nitrite
levels (P ¼ .0125, r ¼ 0.78) (Table 2).
Rhinovirus Infection of Monocytes in vitro
Rhinovirus infection of the monocytic cell line THP-1
resulted in upregulation of the inﬂammatory cytokines
IL-6 and CXCL8/IL-8 (Fig 4). Rhinovirus infection
reduced expression of HDAC2 (both mRNA and
protein) compared with noninfected cells (Figs 4C, 4D),
and reduced HDAC2 activity (Fig 4E). Levels of
nitrosylated HDAC2 were increased postinfection
compared with noninfected cells (Fig 4F). THP-1 cells
were treated with N-acetylcysteine (NAC) to inhibit the
actions of peroxynitrate.18-20 Treatment of the THP-1
cells with NAC led to a dose-dependent reduction injournal.publications.chestnet.orgIL-6 and CXCL8/IL-8, with signiﬁcant reductions in
inﬂammatory mediators observed at doses >1 mM
(Figs 4G, 4H).Discussion
Acute exacerbations are important events in the natural
history of COPD, but their pathogenesis remains poorly
understood. Prevention of exacerbations remains a key
therapeutic goal, but current treatments have only
modest beneﬁts and considerable adverse effects.
Previous work from our group has demonstrated that
experimental rhinovirus infection in subjects with
COPD induces respiratory symptoms, airﬂow
obstruction, and neutrophilic inﬂammation.15 In the
current study, we provide novel evidence of the
mechanisms of virus-induced COPD exacerbations and
identify new potential therapeutic targets.
O&NS, airways inﬂammation, and reduced HDAC
activity are well described in stable COPD, but their
roles in COPD exacerbations are unclear. Some studies
have reported increased inﬂammation and oxidative
stress in exacerbations,3,21-24 whereas others have
reported no change compared with the stable state.25-28
Increased numbers of 3-NT positive cells have been
reported in COPD exacerbations,21 and two studies
reported that HDAC activity is unchanged in
exacerbated COPD.28,29 In these studies of naturally
occurring exacerbations, there are numerous sources of
variability that likely account for their discrepant results,
including variations in exacerbation etiology, timing of
presentation/sampling after exacerbation onset, different
treatments, and so forth, that are difﬁcult to eliminate.
Understanding the molecular pathways in COPD
exacerbations is critical to developing new, more
effective preventive and therapeutic strategies. Our
model of COPD exacerbation permits repeated lower67
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Figure 3 – Time course of oxidative and nitrosative stress markers in sputum and HDAC2 activity in sputum and BAL macrophages during
experimental rhinovirus infection. A, Sputum 8-isoprostane. B, Sputum 8-hydroxy-2’-deoxyguanosine. C, Sputum 3-nitrotyrosine. D, Sputum nitrite.
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HDAC2 ¼ histone deacetylase-2. See Figure 2 legend for expansion of other abbreviation.airway sampling in treatment-naïve subjects in a manner
not possible with naturally occurring exacerbations,
thereby reducing variability and offering unique insights
into the mechanisms of COPD exacerbations.15,16,30,31
Moreover, use of a human model, as opposed to an68 Original Researchanimal model, provides data that are more likely to be
rapidly translated into new therapies. Using this model,
we measured markers of inﬂammation, O&NS, and
HDAC activity prior to and following rhinovirus
infection.[ 1 4 9 # 1 CHES T J A N U A R Y 2 0 1 6 ]
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journal.publications.chestnet.orgWe previously reported that virus-induced
exacerbations are associated with increased neutrophils,
and neutrophil elastase, and CXCL8/IL-8 levels.15 In the
current study, we replicated these ﬁndings in a new
cohort of subjects and, in addition, demonstrated that
virus infection induces signiﬁcant increases in the
proinﬂammatory cytokines GM-CSF, TNF-a, and IL-1b,
and the protease MMP-9. Levels of 8-isoprostane
(a marker of lipid peroxidation), 8-OHdG (a marker of
hydroxyl radical damage to DNA), 3-NT (a product of
tyrosine nitration mediated by peroxynitrite), and nitrite
were signiﬁcantly increased in sputum in the subjects
with COPD, with only small, transient increases in
smokers without COPD. There were positive
correlations between markers of nitrosative stress and
inﬂammatory mediators in sputum. These data provide
new evidence of a pathogenic role of O&NS in COPD
exacerbations. Exacerbations are associated with
accelerated loss of lung function,32-34 and O&NS,35,36
neutrophil elastase,37 and MMP-938 are all associated
with airway remodeling. Therefore, these are potential
mechanisms linking exacerbations with loss of lung
function in COPD.
HDAC2 levels at baseline were not lower in the subjects
with COPD subjects, as has been reported previously in
patients with COPD GOLD stages II and III.8 Reduced
HDAC2 is most pronounced in severe COPD and,
therefore, may not be present in subjects with GOLD
stage II disease. Following rhinovirus infection, there
was a trend toward reduced HDAC2 activity in sputum
and BAL macrophages in subjects with COPD, and
HDAC activity correlated inversely with airways
inﬂammation, virus load, and nitrite levels. Nitrosylation
of HDAC, followed by HDAC degradation, is a
mechanism of reduced HDAC2 activity,39 and our
in vitro data are the ﬁrst report, to our knowledge, that
virus infection induces nitrosylation of HDAC2. The
inverse relationship between airway HDAC2 activity
and nitrite levels following virus infection suggests this is
relevant in vivo also. Therefore, nitrosylation of HDAC2
may link virus infection, O&NS, impaired HDAC2
activity, and enhanced inﬂammation in COPD
exacerbations.
These results have a number of important implications
for our understanding of the pathogenesis of COPD
exacerbations and future therapeutic directions.
Corticosteroids are used in COPD exacerbations despite
modest clinical beneﬁts and frequent adverse effects.5,40
Reduced HDAC2 may contribute to corticosteroid
resistance in stable COPD8 and our results suggest this is69
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Figure 4 – Rhinovirus infection of THP-1 cells in vitro. A, Induction of IL-6 by rhinovirus in THP-1 cells. B, Induction of CXCL-8 by rhinovirus in
THP-1 cells. C, HDAC2 protein in THP-1 cells infected with rhinovirus. D, HDAC2 RNA in THP-1 cells infected with rhinovirus protein. E, HDAC2
activity in THP-1 cells infected with rhinovirus. F, HDAC2 nitrosylation in THP-1 cells infected with rhinovirus. G, Inhibition of rhinovirus-induced
IL-6 by N-acetylcysteine (NAC). H, Inhibition of rhinovirus-induced CXCL8/IL-8 by NAC. Data given as mean  SE of at least three independent
experiments. *P < .05.
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also relevant in exacerbated COPD. Thus, enhancing
HDAC2 activity through inhibiting virus-induced
O&NS has the potential to improve the therapeutic
effect of corticosteroids in COPD exacerbations, as
well as having a direct antiinﬂammatory effect itself.
This warrants investigation in studies speciﬁcally
designed to address this issue. The demonstration
that O&NS and multiple inﬂammatory mediators
and proteases are elevated in exacerbations may account
for the lack of clinical beneﬁt seen with inhibition of
single mediators41-44 and casts doubt on this as a
valid therapeutic approach. NAC, both an antioxidant
and a peroxynitrite inhibitor, demonstrated an
antiinﬂammatory effect in vitro and may also be
effective in vivo.
Reduced baseline HDAC2 activity in sputum
macrophages was associated with greater virus loads
postinfection; therefore, reduced HDAC2 activity may
also be linked to impaired antiviral responses. We
observed signiﬁcantly higher sputum virus loads in
subjects with COPD, conﬁrming for the ﬁrst time, to our
knowledge, impaired antiviral immunity in COPD
results in more severe lower respiratory virus infection.
HDAC activity is required for an effective antiviral
response to picornavirus infection45; therefore, reduced
HDAC activity may contribute to impaired antiviral
host defense and increased severity of clinical illness
following virus infections in COPD.
Our study has a number of limitations that are inherent
to experimental infection studies. The number of
subjects was small and only subjects with moderate
COPD were included; therefore, the ﬁndings may not
be applicable to more severe patients. However, as
HDAC2 activity is further reduced8 and exacerbations
more frequent in severe COPD,2 we believe these
mechanisms are likely to be even more relevant in more
severe disease. Secondary bacterial infections did occurjournal.publications.chestnet.orgin some subjects,30 but the numbers were too small to
allow an analysis of the interactions between HDAC2
activity and bacteria (six subjects with bacterial
infection, three without). Whether changes in HDAC2
activity affect the ability of macrophages to clear
bacteria is a subject of great interest and warrants
further investigation. The smokers were signiﬁcantly
younger compared with the nonsmokers, but there were
no signiﬁcant differences in age between the COPD
group and the two control groups and, as the key
comparisons were between the subjects with COPD
and those without, we do not believe this affected the
important results. Moreover, Ito et al8 reported that age
had no effect on HDAC activity in bronchial biopsies.
However, ideally, subsequent studies should use age-
matched subjects whenever possible to remove this
confounder. We used sputum to measure inﬂammatory
mediators and cells and these do not reﬂect inﬂammation
in the small airways. The main site of rhinovirus
replication is epithelial cells rather than macrophages
and, therefore, the signiﬁcance of the relationship
between HDAC2 levels in macrophages and virus
load is unclear. The in vitro work was carried out in
THP-1 cells rather than alveolar macrophages, as
these are difﬁcult to obtain in large enough numbers
to perform the necessary experiments. However, the
data obtained provide valid mechanistic information as
to the potential mechanisms involved in macrophage
responses to viral infection in COPD.
In summary, we have demonstrated induction of O&NS,
reduced HDAC2 activity, increased inﬂammatory
mediators, and increased virus load in the airways
following rhinovirus infection in subjects with COPD.
These results provide unique insights into the
mechanisms of virus-induced COPD exacerbations and
suggest novel therapeutic targets for the development of
new targeted therapies in COPD.71
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